Richard A. Baron is now vice president and chief financial officer at Zynerba Pharmaceuticals, Inc. of Radnor, a specialty pharmaceutical company that has invested $13 million in innovative trans-dermal synthetic cannabinoid therapies.

Baron has more than 30 years of experience in executive finance leadership with early-stage pharmaceutical and healthcare companies. He was most recently senior vice president and CFO at Globus Medical.

Zynerba states it is the first and only transdermal cannabinoid therapeutic company.  BioWorld reported in October Zynerba raised $13 million in private funds from Perceptive Advisors LLC and other investors. It plans to market two proprietary preclinical compounds intended to treat diseases with significant unmet medical needs.

ZYN001 will be marketed for persons with Fibromyalgia, neuropathic and chronic cancer pain.  ZYN002 is geared toward patients with epilepsy and osteoarthritis.

“Rick has an exemplary track record of successfully helping emerging companies grow to the next level through strategic financing,” said Armando Anido, Zynerba chairman and CEO.  “He will be a valued member of the Zynerba team as we rapidly approach clinical development of these novel trans-dermal synthetic cannabinoid candidates in the coming months and work to take the company to the next stage.”